

# **Transformation/Innovation Opportunities for the NRC to Explore**

## Federal Perspective

**Murray Sheldon, MD**

Center for Devices and Radiological Health  
U.S. Food and Drug Administration

Nuclear Regulatory Commission

Discussion of Medical Uses of Radioactive Materials (public meeting)

Rockville, MD

January 28, 2020



# CDRH Mission and Vision


MISSION: *To Protect and Promote the Public Health. Assure that patients and providers have timely and continued access to safe, effective, and high-quality medical devices*

VISION: *Patients in the US have access to high quality, safe and effective medical devices of public health importance first in the world*

# Long-term Decline in Start-up Density Since 1988




NEW COMPANY FORMATIONS DOWN (1978 - 2012)\*



Stark decline in Medtech since 2006 to ~600 in 2012

\*from: A Future At Risk: Economic Performance, Entrepreneurship, and Venture Capital in the U.S. Medical Technology Sector. Written by Innovation Counsellors LLC with support from AdvaMed Accell October, 2016  
[https://www.advamed.org/sites/default/files/resource/a\\_future\\_at\\_risk\\_advamed\\_october\\_2016.pdf](https://www.advamed.org/sites/default/files/resource/a_future_at_risk_advamed_october_2016.pdf)

# Makower Report (2010): FDA Impact on US Medical Technology Innovation



# Entrepreneurs-in-Residence Program One (Oct 2011 – May 2012)



**Overview:** The Entrepreneurs-in-Residence (EIR) program at CDRH is a time-limited recruitment of world-class entrepreneurs and innovators to join highly-qualified internal government employees in the development of solutions in areas that impact innovation

**Goal:** The EIR goal is to deliver transformational change by combining the best internal and external talent applying the principles of lean engineering in rapidly testing, validating and scaling new approaches

**Focus:** To better understand the drivers for the CDRH vision and to develop a new expedited pathway to improve patient access to innovative medical devices

- ESRD Innovation Challenge (2013 – 2016)
- Breakthrough Devices Program (2018)

# **US Medical Device Industry:** **Innovation Challenges**

Factors cited as having the highest impact on decisions to move medical device investment outside of U.S.\*



\* from National Venture Capital Association/Medical Innovation & Competitiveness Coalition survey of 259 NVCA member firms investing in the healthcare sectors; 60% (156 firms responding) October, 2011

# Entrepreneurs-in-Residence Program Two (Oct 2012 – May 2013)



**Focus:** The EIR teams confronted the three challenging areas identified by NVCA that have the potential to better support a more robust environment for medical device innovation:

- Streamlining clinical trials
- Streamlining FDA approval to reimbursement
- Striking the right balance between pre- and post-market requirements

# FDA Responds to the Challenge

- Clinical Trials Program in ODE based on recommendations from the EiR Program
  - Early feasibility program: 17 approvals in FY 2013; 51 in FY 2019
  - Adaptive and Bayesian design
  - Patient-Centric Benefit/Risk; Patient perspectives
- Payor Communication Task Force to Streamline the path from FDA Approval to Payer Coverage (from EiR)
- Balancing Pre and Post-market Evidentiary Requirements
  - NEST – the use of Real-World Evidence
  - Coordinated Registry Networks (CRNs)



# Continuous Innovation



## Internal Innovation

- Training visits to innovative incubators/accelerators
- Training visits to payors

## Public Private Partnerships

- KHI – American Society of Nephrology and FDA (2012)
- KidneyX – American Society of Nephrology and HHS (2018): Uses prize competitions to accelerate the development of innovative solution that can prevent, diagnose and/or treat kidney diseases

# Thank You



**U.S. FOOD & DRUG**  
ADMINISTRATION

*& Devices*